Request Demo
Last update 09 Mar 2026
Alpha-0261
Last update 09 Mar 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AM 001, AM-001, AM001 + [1] |
Target |
Action modulators |
Mechanism MRGPRX2 modulators(MAS related GPR family member X2 modulators) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Alpha-0261NCT07279636
A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation, Phase Ia Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Oral Administration of Alpha-0261 Tablets in Adult Healthy Participants
CTR20260869
一项评估Alpha-0261片在成年中重度特应性皮炎（AD）试验参与者中的安全性、耐受性、初步有效性、药代动力学及药效学特征的随机、双盲、安慰剂对照、多次给药剂量递增的Ib期临床研究
[Translation] A randomized, double-blind, placebo-controlled, multiple-dose escalation phase Ib clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic and pharmacodynamic characteristics of Alpha-0261 tablets in adult participants with moderate to severe atopic dermatitis (AD).
CTR20253320
评价成年健康研究参与者单次口服Alpha-0261片的安全性、耐受性及药代动力学的随机、双盲、安慰剂对照、剂量递增的Ia期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalating Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetics of a single oral dose of Alpha-0261 in adult healthy study participants
100 Clinical Results associated with Alpha-0261
Login to view more data
100 Translational Medicine associated with Alpha-0261
Login to view more data
100 Patents (Medical) associated with Alpha-0261
Login to view more data
100 Deals associated with Alpha-0261
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | Phase 1 | - | 06 Mar 2026 | |
| Severe Atopic Dermatitis | Phase 1 | - | 06 Mar 2026 | |
| Dermatitis, Atopic | IND Approval | United States | 03 Jun 2025 | |
| Dermatitis, Atopic | IND Approval | China | 03 Jun 2025 | |
| Urticaria | Preclinical | United States | 03 Jun 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free